Information from Oncoinvent AS regarding the newly elected board members and the resignation of CEO Jan Alfheim
Oncoinvent shareholders have recently elected new board members and the board now comprises Roy Larsen (Executive Chairman), Øyvind Bruland, Petter Fjellstad, Thora Jonasdottir, Anne Cecilie Alvik and Mona-Elisabeth Revheim.
Roy Larsen, the founder of the company and the inventor of Radspherin®, will lead the company as Executive Chairman. This following the announcement from Jan Alfheim, Managing director that he is leaving to pursue other opportunities. Roy Larsen will take an active role in the company, while a search for a new CEO is ongoing. Prime focus will be on Radspherin® development while working closely with the Board and Oncoinvent management to chart the course for a successful clinical development of Radspherin®, the company’s lead product candidate.
Alfheim has agreed to stay in an advisory position to ensure a smooth and professional transition for a number of months. Jan has been instrumental in the company’s development and the Board wishes him all the best wherever he decides to go.
About Oncoinvent AS.
Oncoinvent AS is a clinical stage company developing innovative radiopharmaceutical technology that delivers precise, alpha-emitting particles across various cancers. By leveraging internal manufacturing and supply chain capabilities to enable a clinical supply of radioisotopes, the company is advancing therapy based on alpha particles, a higher Linear Energy Transfer (LET) form of radiation, that can potentially eradicate cancer cells. Oncoinvent’s lead candidate, Radspherin®, is designed for treatment of metastatic cancers in body cavities, and its versatility allows it to be deployed for the treatment of a variety of cancer indications. The Company has two ongoing clinical studies (Phase 2a) where patients with peritoneal carcinomatosis, from ovarian cancer and colorectal cancer are treated with Radspherin®.
For further information, please contact:
Tore Kvam, CFO
Cell: +47 95934199